CJ 바이오사이언스

311690KOSDAQ자연과학 및 공학 연구개발업

50.8 / 100

Reference Date: 2026-07-24

Financial Score19.0 / 40

News Sentiment18.8 / 25

Momentum3.0 / 20

Disclosure10.0 / 15

AI Analysis: PBR is significantly undervalued vs. peers but Revenue is on a declining trend. Plunged 15.1% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

CJ BioScience operates core businesses including AI-powered microbiome analysis platforms (Ez-Mx®) for drug development, microbial genome analysis solutions, and health & wellness services (e.g., GUT INSIDE, SMILE GUT). The company has strategically shifted focus toward health & wellness, expanding consumer-accessible AI-based gut health diagnostic services in 2025. The majority of revenue comes from its microbiome genome analysis platform, EzBioCloud.

Number of Employees

102people

Average Salary

79.3M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 43.644.0Point

PBR

0.91Industry Average 2.527.0Point

Half of industry avg (excellent)

ROE

-36.54Industry Average -32.093.5Point

In line with industry avg

Debt Ratio

7.72Industry Average 7.312.0Point

Higher than industry avg (caution)

Trend 2023~20252.5 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼15.7% (2-year basis)

Operating Profit Growth Rate

2.5 / 3

Avg ▲10.4% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -39.5% (improving, 3yr)

Detailed News Sentiment

2 totalPositive 1Neutral 0Negative 1Average Sentiment Score 75

Negative
[단독]주력사업 부진에… 돈 안되는 ‘미래 먹거리’ 손턴다
CJ 바이오사이언스의 해외 바이오 자회사 청산 논의는 경제 불황 속에서 미래 성장 동력 확보에 어려움을 겪고 있음을 시사한다.
Positive
CJ바이오, 장내 미생물 기반 '정밀 영양 통합 플랫폼' 공개
CJ바이오사이언스의 새로운 장내 미생물 기반 정밀 영양 통합 플랫폼 공개로 기술 혁신과 연구 역량 강화 기대.

Detailed Momentum

52-week position1.0Point

Near 52w low (1%, downtrend)

Current 3,735Won52-week high 10,29052-week low 3,635

1-month return0.0Point

1m -15.11% (strong drop)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

0 totalPositive 0Neutral 0Negative 0